Statements (13)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:alternativeName |
talnetant
|
| gptkbp:ATCCode |
none
|
| gptkbp:CASNumber |
177404-21-6
|
| gptkbp:clinicalTrialPhase |
discontinued
|
| gptkbp:developedBy |
GlaxoSmithKline
|
| https://www.w3.org/2000/01/rdf-schema#label |
CVP-701
|
| gptkbp:intendedUse |
treatment of schizophrenia
treatment of irritable bowel syndrome |
| gptkbp:mechanismOfAction |
neurokinin-3 receptor antagonist
|
| gptkbp:bfsParent |
gptkb:CVP_series
gptkb:Clavinova_CVP |
| gptkbp:bfsLayer |
7
|